EUVIMEDEUVIMED entdecken
Crossref

Treatment effectiveness of hydroxychloroquine in patients with primary Sjögren’s syndrome: a real-world Study

Kexin Zhu, Xueyi Zhang, Guangcai Chen, Ying Zhu, Kai Wang, Qing Zhang, Ziyi Jin, Qing Shu, Xiaojun Tang, Hongwei Chen, Dandan Wang, Wei Shen und 1 weitere

Clinical Rheumatology · 2025

DOI: 10.1007/s10067-025-07583-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Rheumatology, 2025. Verfasst von Kexin Zhu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Hydroxychloroquine, Sjogren's Syndrome, Antirheumatic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Nanjing Health Technology Development, Nanjing Drum Tower Hospital, Jiangsu Medical Innovation Team.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: This study aimed to evaluate the effectiveness of hydroxychloroquine (HCQ) in reducing disease activity and explore its optimal dosing and combination therapies in patients with primary Sjögren's syndrome (pSS). METHODS: We conducted a retrospective study of 1089 hospitalized pSS patients. Multivariable logistic regression was used to estimate adjusted odds ratios (ORs) with 95% confidence intervals (CIs). Propensity score matching (PSM) was performed to assess robustness. RESULTS: Compared to non-users, patients receiving HCQ at daily doses of 300 mg (OR = 2.50, 95% CI 1.08-5.77), 400 mg (OR = 1.66, 95% CI 1.21-2.27), or > 5 mg/kg (OR = 1.71, 95% CI 1.25-2.34) showed higher response rates. Subgroup analyses suggested greater HCQ effectiveness in patients aged ≤ 50 years, without hypertension or diabetes, with SSA/RF seropositivity, no prior HCQ exposure, baseline ESSDAI scores of 5-13, concomitant glucocorticoids (GCs) use (> 20 mg/day), normal C3 level, or low C4 levels. The combination of GCs, cyclosporin A, and HCQ demonstrated a numerically higher response rate than GCs plus cyclosporin A alone (OR = 3.73, 95% CI 1.19-11.72). HCQ was associated with improved outcomes in thrombocytopenia (OR = 1.81, 95% CI 1.01-3.25), hypoalbuminemia (OR = 1.72, 95% CI 1.24-2.38), and elevated erythrocyte sedimentation rate (ESR) (OR = 2.25, 95% CI 1.42-3.58). CONCLUSION: HCQ at daily doses of 300 mg, 400 mg, or > 5 mg/kg may reduce disease activity in pSS patients, particularly in specific subgroups. The combination of GCs, cyclosporin A, and HCQ warrants further investigation as a potential therapeutic strategy. HCQ might also benefit patients with thrombocytopenia, hypoalbuminemia, or elevated ESR. Key Points • A daily HCQ dosage of 300 mg, 400 mg or >5 mg/kg effectively reduced disease activity in pSS patients. • HCQ demonstrated therapeutic efficacy in specific pSS patient subgroups. • Glucocorticoids, cyclosporin A and HCQ may be a promising drug combination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HydroxychloroquineSjogren's SyndromeAntirheumatic AgentsHumansFemaleMaleMiddle AgedRetrospective StudiesTreatment OutcomeAdultAgedDrug Therapy, CombinationPropensity ScoreGlucocorticoidsCyclosporineLogistic Models

Stichwörter der Autor:innen

Disease activityDrug combinationHydroxychloroquinePrimary Sjögren’s syndromeTreatment effectiveness

Substanzen

HydroxychloroquineAntirheumatic AgentsGlucocorticoidsCyclosporine

Autor:innen und Institutionen

  • Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, China.
  • Hospital of Chengdu Office of People's Government of Tibetan Autonomous Region (Hospital.C.T.), Chengdu, China.
  • Department of Pharmacy, Wuhan Pulmonary Hospital, Wuhan, China.
  • Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
  • Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
  • Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, China. shenweiqh@163.com.

Förderung

  • Nanjing Health Technology Development
  • Nanjing Drum Tower Hospital
  • Jiangsu Medical Innovation Team

Zitieren

APA

Zhu, K., Zhang, X., Chen, G., Zhu, Y., Wang, K., Zhang, Q., Jin, Z., Shu, Q., Tang, X., Chen, H., Wang, D., Shen, W., & Sun, L. (2025). Treatment effectiveness of hydroxychloroquine in patients with primary Sjögren’s syndrome: a real-world Study. Clinical Rheumatology. https://doi.org/10.1007/s10067-025-07583-w

Vancouver

Zhu K, Zhang X, Chen G, Zhu Y, Wang K, Zhang Q, et al. Treatment effectiveness of hydroxychloroquine in patients with primary Sjögren’s syndrome: a real-world Study. Clinical Rheumatology. 2025. doi:10.1007/s10067-025-07583-w

BibTeX
@article{Zhu2025,
  author = {Zhu, Kexin and Zhang, Xueyi and Chen, Guangcai and Zhu, Ying and Wang, Kai and Zhang, Qing and Jin, Ziyi and Shu, Qing and Tang, Xiaojun and Chen, Hongwei and Wang, Dandan and Shen, Wei and Sun, Lingyun},
  title = {Treatment effectiveness of hydroxychloroquine in patients with primary Sjögren’s syndrome: a real-world Study},
  journal = {Clinical Rheumatology},
  year = {2025},
  doi = {10.1007/s10067-025-07583-w}
}
Kostenlos starten →